This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT02829268
First received: July 6, 2016
Last updated: March 24, 2017
Last verified: March 2017
July 6, 2016
March 24, 2017
January 2017
December 2018   (Final data collection date for primary outcome measure)
Number of participants with treatment-related adverse events as assessed by liver function tests [ Time Frame: 6 months ]

The investigators assess the safety and tolerability of dantrolene sodium administered orally at upper end of therapeutic dose range for 6 months in patients with Wolfram syndrome. More specifically, the investigators perform liver function tests to check the levels of certain enzymes and proteins in participants' blood. Levels that are higher or lower than normal can indicate liver problems. The liver function tests include:

Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline Phosphatase (AP), and bilirubin.

Number of participants with treatment-related adverse events as assessed by liver function tests [ Time Frame: 6 months ]

The investigators assess the safety and tolerability of dantrolene sodium administered orally at upper end of therapeutic dose range for 6 months in patients with Wolfram syndrome. More specifically, the investigators perform liver function tests to check the levels of certain enzymes and proteins in participants' blood. Levels that are higher or lower than normal can indicate liver problems. The liver function tests include:

Alanine transaminase (ALT) and Aspartate transaminase (AST).

Complete list of historical versions of study NCT02829268 on ClinicalTrials.gov Archive Site
  • Changes in C-peptide levels in participants assessed by the ELISA assay [ Time Frame: 6 months ]
    The investigators determine the effect of dantrolene sodium on residual beta cell functions. The investigators monitor base-line C-peptide levels in participants' blood. The investigators also monitor C-peptide levels in participant's blood during the oral mixed meal tolerance test. The night before the oral mixed meal tolerance test, the participants will turn their insulin pump basal rate to 50% of the normal rate at midnight or take half of their evening dose of Lantus insulin and fasted from midnight until the test at 8 a.m. The mixed meal consists of 6 ml/kg (maximum 360 ml) of Boost Original (Société des Produits Nestlé S.A., Vevey, Switzerland). Blood for glucose and C-peptide measurement will be drawn at time 0 (fasting) and 30 minutes after the Boost. If a subject's fasting glucose exceeds 11.1 mmol/l, the test will not be performed, but fasting glucose and C-peptide will be obtained.
  • Changes in Visual Functioning in participants assessed by Visual Functioning Questionnaire-25. [ Time Frame: 6 months ]
    Visual functions will be assessed by Visual Functioning Questionnaire - 25.
  • Changes in best-corrected visual acuity in participants measured by Snellen optotype [ Time Frame: 6 months ]
    Best-corrected visual acuity will be measured by Snellen optotype. Higher logMar scores indicate worse vision.
  • Changes in Neurological Functions in participants assessed by the Wolfram Unified Rating Scale (WURS) [ Time Frame: 6 months ]
    Neurological functions will be assessed by the Wolfram Unified Rating Scale (WURS) and standard neurological assessments.
  • Changes in C-peptide levels in participants assessed by the ELISA assay [ Time Frame: 6 months ]
    The investigators determine the effect of dantrolene sodium on residual beta cell functions. The investigators monitor base-line C-peptide levels in participants' blood. The investigators also monitor C-peptide levels in participant's blood during the oral mixed meal tolerance test. The night before the oral mixed meal tolerance test, the participants will turn their insulin pump basal rate to 50% of the normal rate at midnight or take half of their evening dose of Lantus insulin and fasted from midnight until the test at 8 a.m. The mixed meal consists of 6 ml/kg (maximum 360 ml) of Boost Original (Société des Produits Nestlé S.A., Vevey, Switzerland). Blood for glucose and C-peptide measurement will be drawn at time 0 (fasting) and 30 minutes after the Boost. If a subject's fasting glucose exceeds 11.1 mmol/l, the test will not be performed, but fasting glucose and C-peptide will be obtained.
  • Changes in dynamic balance in participants assessed by the Mini-Balance Evaluation Systems Test (Mini BESTest) [ Time Frame: 6 months ]
    Balance will be measured by the Mini-Balance Evaluation Systems Test (Mini BESTest). The Mini BESTest is a clinician rated assessment of dynamic balance. Lower scores are indicative of impairments in balance. The total possible score on this evaluation is 28, indicating no balance impairmen
  • Changes in best-corrected visual acuity in participants measured by Snellen optotype [ Time Frame: 6 months ]
    Best-corrected visual acuity will be measured by Snellen optotype. Higher logMar scores indicate worse vision)
Not Provided
Not Provided
 
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome

Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Wolfram Syndrome
  • Diabetes Mellitus
  • Optic Nerve Atrophy
  • Ataxia
Drug: dantrolene sodium

The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

  • Experimental: Pediatric
    Pediatric patients treated with dantrolene sodium
    Intervention: Drug: dantrolene sodium
  • Experimental: Adult
    Adult patients treated with dantrolene sodium
    Intervention: Drug: dantrolene sodium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
March 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for enrolment:

  1. The patient has a definitive diagnosis of Wolfram syndrome, as determined by the following:

    a. Documented functionally relevant recessive mutations on both alleles of the WFS1 gene or dominant mutation on one allele of the WFS1 gene based on historical test results (if available) or from a qualified laboratory at screening.

  2. The patient is at least 5 years of age (biological age) at the time of written informed consent.
  3. The patient, patient's parent(s), or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient. The guardians' consent and patient's assent, as relevant, must be obtained.

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for this study:

  1. The patient has clinically significant non-Wolfram related CNS involvement which is judged by the investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.
  2. The patient has a known defect in oxidative phosphorylation (such as a confirmed mitochondrial myopathy)
  3. The patient has abnormal liver function (defined as serum transaminases more than twice the upper limit of normal for the reference laboratory)
  4. The patient has a significant medical or psychiatric co-morbidity that might affect study data or confound the integrity of study results.
  5. The patient has received treatment with any investigational drug within the 30 days prior to study entry.
  6. The patient has received blood product transfusions within 90 days prior to screening.
  7. The patient is unable to comply with the protocol, (e.g. has a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioural instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.
  8. The patient has a known history of central apnea and/or ventilation requirements.
  9. The patient has a known history of chronic obstructive pulmonary disease, pleural effusion, and/or myocardial disease.
Sexes Eligible for Study: All
5 Years to 60 Years   (Child, Adult)
No
Contact: Ashley N Simpson, RN, BSN, CPN +1-314-286-1550 ashley.simpson@wustl.edu
Contact: Teresa Arb, RN, BSN, CCRC +1-314-747-1217 arbt@wustl.edu
United States
 
 
NCT02829268
201607006
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: publication
Washington University School of Medicine
Washington University School of Medicine
Not Provided
Study Director: Fumihiko Urano, MD Washington University School of Medicine
Washington University School of Medicine
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP